UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): January 4, 2013
Apricus Biosciences, Inc.
(Exact name of registrant as specified in its charter)
| Nevada |
0-22245 |
87-0449967 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) | (I.R.S. Employer Identification No.) |
| 11975 El Camino Real, Suite 300, San Diego, California |
92130 | |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: (858) 222-8041
| Not Applicable |
||||
| Former name or former address, if changed since last report |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
1
Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.
On January 4, 2013, Henry Esber, Ph.D. tendered his resignation as a member of the board of directors (the “Board”) of Apricus Biosciences, Inc. (the “Company”), effective immediately. Dr. Esber did not serve on any committees of the Board at the time of his resignation. Dr. Esber resigned for personal reasons and his resignation was not related to a disagreement with the Company.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| January 7, 2013 | Apricus Biosciences, Inc. | |||||||||||||||||||
| By: | /s/ Randy Berholtz |
|||||||||||||||||||
| Randy Berholtz | ||||||||||||||||||||
| Executive Vice President, General Counsel and Secretary |
||||||||||||||||||||
3